Assembly Biosciences, Inc. (ASMB) Income Statement
ASMB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsASMB revenue and net income
Where ASMB's revenue goes
2025Each bar shows an amount and its share of revenue. ASMB kept −8.5% of revenue as net income.
ASMB profit margins
ASMB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +153.5% | — | −1.8% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ASMB quarterly EPS vs estimates
Assembly Biosciences beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.44).
ASMB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | $7.2M | $0 | $6.3M | $79.1M | $16.0M | $14.8M | $9.0M | $0 |
| Cost of revenue | $129,000 | $55.9M | $48.9M | $498,000 | $466,000 | $101.3M | $85.8M | $72.7M | $44.2M | $80,251 |
| Gross profit | $72.2M | −$27.4M | −$41.7M | −$498,000 | $6.3M | −$22.2M | $16.0M | −$57.9M | −$35.2M | −$80,251 |
| Research & development | $64.8M | $55.9M | $48.9M | $70.0M | $68.5M | $106.8M | $85.8M | $72.7M | $44.2M | $33.1M |
| Sales, general & admin | $19.6M | $18.0M | $22.9M | $24.1M | $28.8M | $36.9M | $32.9M | $34.8M | $17.0M | $12.2M |
| Total operating expenses | $84.4M | $18.0M | $22.9M | $94.1M | $138.9M | $42.5M | $118.7M | $107.5M | $61.2M | $45.3M |
| Operating income | −$12.1M | −$45.4M | −$64.6M | −$94.1M | −$132.7M | −$64.8M | −$102.7M | −$92.7M | −$52.2M | −$45.3M |
| Interest income | $6.0M | $5.6M | $2.4M | $1.0M | $302,000 | $2.6M | $4.3M | $3.1M | $983,209 | $1.5M |
| Interest expense | — | — | — | $498,000 | $82.5M | $2.6M | $4.8M | $0 | $0 | $0 |
| Income before taxes | −$6.1M | −$39.8M | −$61.2M | −$93.1M | −$132.4M | −$62.2M | −$98.4M | −$89.7M | −$51.9M | −$44.9M |
| Income taxes | — | $330,000 | $33,000 | −$1.0M | −$2.5M | −$2.6M | −$774,000 | $1.1M | −$9.1M | −$617,672 |
| Net income | −$6.1M | −$40.2M | −$61.2M | −$92.1M | −$129.9M | −$62.2M | −$97.6M | −$90.8M | −$42.8M | −$44.3M |
| EBITDA | −$6.0M | −$39.7M | −$60.7M | −$93.6M | −$90.6M | −$58.4M | −$102.2M | −$92.7M | −$52.0M | −$44.8M |
| EPS (diluted) | −$0.74 | −$6.72 | −$13.67 | −$18.10 | −$20.18 | −$8.88 | −$33.75 | −$36.67 | −$19.05 | −$17.31 |
| Gross margin | 99.8% | −96.1% | −582.7% | — | 100.0% | −28.1% | 100.0% | −391.4% | −390.4% | — |
| Operating margin | −16.8% | −159.3% | −902.5% | — | −2,121.7% | −81.9% | −643.4% | −626.4% | −579.1% | — |
| Net margin | −8.5% | −140.9% | −854.8% | — | −2,076.4% | −78.6% | −611.6% | −613.0% | −474.7% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.4M | $8.2M | $42.5M | $10.8M | $9.6M | $9.4M | $7.4M | $6.8M | $8.5M | $5.8M | $7.2M | $0 |
| Cost of revenue | $20,000 | $26,000 | $32,000 | $16.6M | $16.1M | $14.9M | $14.3M | $13.5M | $32,000 | $32,000 | $84,000 | $10.8M |
| Gross profit | $13.4M | $8.2M | $42.4M | −$5.8M | −$6.5M | −$5.4M | −$6.9M | −$6.7M | $8.5M | $5.8M | $7.1M | −$10.8M |
| Research & development | $14.9M | $14.9M | $17.2M | $16.6M | $16.1M | $14.9M | $14.3M | $13.5M | $16.3M | $11.9M | $11.0M | $10.8M |
| Sales, general & admin | $4.8M | $4.7M | $5.4M | $5.1M | $4.6M | $4.5M | $4.6M | $4.3M | $4.5M | $4.7M | $8.8M | $4.2M |
| Total operating expenses | $19.7M | $19.6M | $22.7M | $5.1M | $4.6M | $4.5M | $4.6M | $4.3M | $20.7M | $16.5M | $19.6M | $4.2M |
| Operating income | −$6.3M | −$11.4M | $19.8M | −$10.9M | −$11.1M | −$9.9M | −$11.5M | −$11.0M | −$12.2M | −$10.7M | −$12.6M | −$15.0M |
| Interest income | $2.5M | $2.3M | $2.3M | $1.7M | $895,000 | $1.1M | $1.1M | $1.3M | $1.5M | $1.7M | $1.6M | $628,000 |
| Income before taxes | −$3.9M | −$9.1M | $22.1M | −$9.2M | −$10.2M | −$8.8M | −$10.3M | −$9.6M | −$10.7M | −$9.1M | −$10.9M | −$14.4M |
| Income taxes | — | — | — | — | — | — | $75,999 | — | $406,000 | −$11,276 | $33,000 | −$116,000 |
| Net income | −$3.9M | −$9.1M | $22.1M | −$9.2M | −$10.2M | −$8.8M | −$10.3M | −$9.6M | −$11.2M | −$9.1M | −$11.0M | −$14.4M |
| EBITDA | −$3.8M | −$9.1M | $22.1M | −$9.2M | −$10.2M | −$8.8M | −$10.2M | −$9.6M | −$10.7M | −$9.0M | −$10.8M | −$14.3M |
| EPS (diluted) | −$0.20 | −$0.54 | $2.48 | −$0.72 | −$1.33 | −$1.17 | −$1.57 | −$1.51 | −$1.98 | −$1.66 | −$2.15 | −$3.24 |
| Gross margin | 99.9% | 99.7% | 99.9% | −53.7% | −67.5% | −57.7% | −94.1% | −97.4% | 99.6% | 99.4% | 98.8% | — |
| Operating margin | −47.4% | −138.4% | 46.6% | −100.9% | −115.2% | −105.5% | −156.7% | −160.1% | −143.0% | −185.5% | −175.2% | — |
| Net margin | −28.8% | −110.5% | 52.0% | −85.2% | −105.9% | −93.6% | −140.5% | −140.4% | −130.7% | −156.9% | −153.0% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ASMB's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ASMB financial results
In fiscal year 2025 (ended December 31, 2025), Assembly Biosciences reported revenue of $72.3 million, up 153.5% from the year before. It had a net loss of $6.1 million, a net profit margin of −8.5%. Diluted earnings per share came to −$0.74. Over five years revenue grew at an average rate of −1.8% a year.
See the ASMB stock overview for the latest quote and news, or the ASMB chart for price history and technical indicators.
ASMB income statement FAQ
What is Assembly Biosciences's annual revenue?
Assembly Biosciences reported total revenue of $72.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 153.5% from $28.5 million the previous year.
Is Assembly Biosciences profitable?
No. Assembly Biosciences reported a net loss of $6.1 million in fiscal 2025, a net profit margin of −8.5%; its operating margin was −16.8%.
What is Assembly Biosciences's gross margin?
Assembly Biosciences's gross margin was 99.8% in fiscal 2025: for every $100 of revenue, Assembly Biosciences kept $100 after the direct cost of its products and services.
How much does Assembly Biosciences spend on research and development?
Assembly Biosciences spent $64.8 million on research and development in fiscal 2025, 89.6% of revenue.
How fast is Assembly Biosciences growing?
Revenue grew −1.8% a year on average over the last five fiscal years, from $79.1 million to $72.3 million.
What are Assembly Biosciences's earnings per share?
Assembly Biosciences earned $-0.74 per diluted share in fiscal 2025, compared with $-6.72 a year earlier.
When will Assembly Biosciences report its next earnings?
Assembly Biosciences is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Assembly Biosciences's fiscal year end?
Assembly Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.